Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) was downgraded by analysts at HSBC from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, The Fly reports.
FSNUY has been the subject of several other reports. Credit Suisse Group boosted their price target on Fresenius SE & Co. KGaA from €35.00 ($36.84) to €38.00 ($40.00) in a research note on Friday. Berenberg Bank upped their target price on Fresenius SE & Co. KGaA from €55.95 ($58.89) to €60.25 ($63.42) and gave the stock a “buy” rating in a research note on Wednesday, February 16th. Zacks Investment Research upgraded Fresenius SE & Co. KGaA from a “sell” rating to a “hold” rating in a research note on Tuesday, April 26th. JPMorgan Chase & Co. cut their target price on Fresenius SE & Co. KGaA from €42.30 ($44.53) to €34.50 ($36.32) and set a “neutral” rating for the company in a research note on Thursday, February 24th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on Fresenius SE & Co. KGaA from €38.00 ($40.00) to €36.00 ($37.89) and set a “hold” rating for the company in a research note on Friday, February 25th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $44.85.
Shares of FSNUY stock opened at $9.03 on Tuesday. The company has a current ratio of 1.13, a quick ratio of 0.85 and a debt-to-equity ratio of 0.64. The stock has a market cap of $20.17 billion, a P/E ratio of 9.31 and a beta of 1.24. The stock has a 50 day simple moving average of $8.93 and a 200 day simple moving average of $9.82. Fresenius SE & Co. KGaA has a 1 year low of $7.37 and a 1 year high of $14.81.
About Fresenius SE & Co. KGaA (Get Rating)
Fresenius SE & Co KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
- Get a free copy of the StockNews.com research report on Fresenius SE & Co. KGaA (FSNUY)
- Intuitive Surgical is an Intuitive Buy
- Follow The Money To Cigna
- The Low In Lordstown Motors May Not Be The Last
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
- Institutional Support For Tyson Foods Is Growing
Receive News & Ratings for Fresenius SE & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.